PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27469405-4	2016	Moreover, treatment with dinaciclib led to the inhibition of oncogenic pathways normally activated in stimulated CLL cells, such as STAT3, NF-kappaB, p38, PI3K/AKT and RAF/MEK/ERK.	dinaciclib	25-35	mitogen-activated protein kinase 1	Homo sapiens	176-179	
33030957-4	2021	Inhibition of MEK/ERK by cobimetinib or CDK inhibitor dinaciclib was shown to attenuate mutant BRAF-induced PD-L1 coincident with reduced c-JUN and YAP expression whose combined knockdown reduced PD-L1.	dinaciclib	54-64	mitogen-activated protein kinase 1	Homo sapiens	18-21